Table 2.

Multivariate analysis for 5 year survival^a

	Hazard ratio	95 % C.I.	P value	Hazard ratio	95 % C.I.	P value	Hazard ratio	95 % C.I.	P value
Age at diagonosis
<35 versus 35–50	1.73	1.42–2.10	<.001	1.52	1.09–2.13	0.098	1.58	1.16–2.15	0.004
Over 50 versus 35–50	0.99		0.821	1.14	0.98–1.34	0.015	1.52	1.33–1.75	<.001
T
T2–4 versus T0, 1	2.22	0.90–1.09	<.001	3.04	2.49–3.70	<.001	2.25	1.96–2.59	<.001
N
Positive versus negative	2.81	2.01–2.46	<.001	4.01	3.46–4.64	<.001	3.05	2.72–3.43	<.001
Breast cancer subtype
ER+HER2+ versus ER+HER2−	1.52	2.58–3.07	<.001	1.73	1.35–2.23	<.001	1.39	1.13–1.72	0.002
ER−HER2+ versus ER+HER2−	1.86	1.65–2.11	<.001	2.33	1.89–2.88	<.001	1.75	1.47–2.07	<.001
Triple negative versus ER + HER2−	2.06	1.86–2.28	<.001	4.48	3.84–5.23	<.001	3.08	2.72–3.50	<.001
Adjuvant therapy
Any versus none	0.87	0.76–1.00	0.041	1.32	1.03–1.71	0.032	0.70	0.60–0.81	<.001

Bold P value < 0.05

^a DFS disease-free survival, BCSS breast cancer specific survival, OS overall survival; TNM classification is shown based on the 6th edition of the Unio Internationalis Contra Cancrum staging system; ER estrogen receptor, HER2 human epidermal growth factor receptor 2